Your browser doesn't support javascript.
Antibody responses after COVID-19 infection in patients who are mildly symptomatic or asymptomatic in Bangladesh.
Shirin, Tahmina; Bhuiyan, Taufiqur Rahman; Charles, Richelle C; Amin, Shaheena; Bhuiyan, Imran; Kawser, Zannat; Rahat, Asifuzaman; Alam, Ahmed Nawsher; Sultana, Sharmin; Aleem, Md Abdul; Khan, Manjur Hossain; Khan, Samsad Rabbani; LaRocque, Regina C; Calderwood, Stephen B; Ryan, Edward T; Slater, Damien M; Banu, Sayera; Clemens, John; Harris, Jason B; Flora, Meerjady Sabrina; Qadri, Firdausi.
  • Shirin T; Institute of Epidemiology, Disease Control and Research, Dhaka, Bangladesh.
  • Bhuiyan TR; Infectious Diseases Division, icddr,b, Mohakhali, Dhaka, Bangladesh.
  • Charles RC; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA; Departments of Medicine and Pediatrics, Harvard Medical School, Boston, MA, USA.
  • Amin S; Infectious Diseases Division, icddr,b, Mohakhali, Dhaka, Bangladesh.
  • Bhuiyan I; Institute for Developing Science & Health Initiatives (ideSHi), Dhaka, Bangladesh.
  • Kawser Z; Institute for Developing Science & Health Initiatives (ideSHi), Dhaka, Bangladesh.
  • Rahat A; Institute for Developing Science & Health Initiatives (ideSHi), Dhaka, Bangladesh.
  • Alam AN; Institute of Epidemiology, Disease Control and Research, Dhaka, Bangladesh.
  • Sultana S; Institute of Epidemiology, Disease Control and Research, Dhaka, Bangladesh.
  • Aleem MA; Infectious Diseases Division, icddr,b, Mohakhali, Dhaka, Bangladesh.
  • Khan MH; Institute of Epidemiology, Disease Control and Research, Dhaka, Bangladesh.
  • Khan SR; Institute of Epidemiology, Disease Control and Research, Dhaka, Bangladesh.
  • LaRocque RC; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA; Departments of Medicine and Pediatrics, Harvard Medical School, Boston, MA, USA.
  • Calderwood SB; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA; Departments of Medicine and Pediatrics, Harvard Medical School, Boston, MA, USA.
  • Ryan ET; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA; Departments of Medicine and Pediatrics, Harvard Medical School, Boston, MA, USA; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Slater DM; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.
  • Banu S; Infectious Diseases Division, icddr,b, Mohakhali, Dhaka, Bangladesh.
  • Clemens J; Infectious Diseases Division, icddr,b, Mohakhali, Dhaka, Bangladesh.
  • Harris JB; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA; Departments of Medicine and Pediatrics, Harvard Medical School, Boston, MA, USA.
  • Flora MS; Institute of Epidemiology, Disease Control and Research, Dhaka, Bangladesh.
  • Qadri F; Infectious Diseases Division, icddr,b, Mohakhali, Dhaka, Bangladesh. Electronic address: fqadri@icddrb.org.
Int J Infect Dis ; 101: 220-225, 2020 Dec.
Article in English | MEDLINE | ID: covidwho-813629
ABSTRACT

OBJECTIVES:

Studies on serological responses following coronavirus disease-2019 (COVID-19) have been published primarily in individuals who are moderately or severely symptomatic, but there are few data from individuals who are mildly symptomatic or asymptomatic.

METHODS:

We measured IgG, IgM, and IgA to the receptor-binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using enzyme-linked immunosorbent assay in mildly symptomatic (n = 108) and asymptomatic (n = 63) on days 1, 7, 14, and 30 following RT-PCR confirmation in Bangladesh and when compared with pre-pandemic samples, including healthy controls (n = 73) and individuals infected with other viruses (n = 79).

RESULTS:

Mildly symptomatic individuals developed IgM and IgA responses by day 14 in 72% and 83% of individuals, respectively, while 95% of individuals developed IgG response, and rose to 100% by day 30. In contrast, individuals infected with SARS-CoV-2 but who remained asymptomatic developed antibody responses significantly less frequently, with only 20% positive for IgA and 22% positive for IgM by day 14, and 45% positive for IgG by day 30 after infection.

CONCLUSIONS:

These results confirm immune responses are generated following COVID-19 who develop mildly symptomatic illness. However, those with asymptomatic infection do not respond or have lower antibody levels. These results will impact modeling needed for determining herd immunity generated by natural infection or vaccination.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Carrier State / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Observational study Topics: Vaccines Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2020 Document Type: Article Affiliation country: J.ijid.2020.09.1484

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Carrier State / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Observational study Topics: Vaccines Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2020 Document Type: Article Affiliation country: J.ijid.2020.09.1484